CELGENE CORP /DE/ CELG Cash Flow

Celgene corp /de/ (CELG)

CashFlow / Quarterly

Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09
Cash flows from operating activities:
Net income
1,691,000	1,571,000	1,545,000	1,073,000	1,082,000	1,045,000	846,000	-81,000	988,000	1,101,000	932,000	429,000	171,000	598,000	801,000	561,000	-34,100	356,200	718,900	613,900	508,500	597,800	279,700	214,400	372,500	478,100	384,900	263,100	424,200	367,400	401,500	410,122	372,984	279,208	255,086	209,247	281,151	155,352	234,442	254,215	216,815	142,834	162,883
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation
48,000	47,000	47,000	41,000	40,000	41,000	38,000	34,000	34,000	34,000	32,000	31,000	32,000	29,000	29,000	28,400	28,800	29,700	28,100	26,200	26,000	26,600	25,500	25,100	24,400	24,200	23,200	25,000	21,400	19,900	18,600	18,149	18,032	17,738	17,281	15,354	13,410	13,519	11,951	12,011	10,409	9,741	9,521
Amortization
123,000	111,000	110,000	129,000	129,000	129,000	88,000	82,000	81,000	90,000	84,000	107,000	85,000	79,000	113,000	93,200	62,500	64,700	66,600	61,800	66,900	64,800	71,600	72,200	69,200	68,100	67,700	65,600	46,400	44,600	42,000	75,739	75,712	70,572	69,677	68,807	46,824	47,349	41,875	16,282	21,577	22,765	23,762
Impairment charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22,400	21,000	3,500	2,100	-	-	-	-	86,600	0	9,500	9,300	83,100	42,700	100	22,100	0	0	0	118,000	-	-	-	-	-	-	-	-
Allocation of prepaid royalties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	470	6,120	9,624	9,942	12,832	11,861	12,606	9,936	9,556	8,709	7,844
Provision for accounts receivable allowances
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,100	2,800	2,700	3,025	1,970	1,214	191	-824	233	-453	-1,265	-1,176	1,220	1,378	1,242
Deferred income taxes
59,000	-38,000	-41,000	42,000	33,000	9,000	-52,000	-1,135,000	-9,000	-106,000	-80,000	-87,000	-90,000	-124,000	-43,000	380,100	-160,500	-146,000	-106,600	-23,700	-67,500	-100,700	-80,400	-85,100	-66,600	-41,800	-53,100	-43,400	-31,100	341,200	-166,500	15,710	-16,228	-20,368	-64,914	-67,069	-1,921	-24,797	-10,136	8,032	-13,771	-9,519	-11,681
Change in value of contingent consideration and success payments
-1,000	-47,000	30,000	-55,000	97,000	7,000	-30,000	-1,425,000	49,000	-13,000	39,000	9,000	23,000	-44,000	33,000	9,200	-6,900	-29,300	19,000	37,700	1,500	900	8,600	91,600	33,800	12,500	33,200	192,700	-700	-38,000	12,400	-270,047	11,378	11,634	99,535	6,985	-5,943	-5,892	-4,862	-	-	-	-
Gain on sale of business
-	-	-	-	-	-	-	-	-	-	-	0	0	0	38,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss on sales of debt securities available-for-sale
0	0	0	0	0	0	-18,000	61,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value adjustments on equity investments
-222,000	-147,000	269,000	-513,000	-124,000	-5,000	959,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Share-based compensation expense
176,000	225,000	257,000	190,000	239,000	284,000	208,000	162,000	159,000	170,000	153,000	154,000	148,000	158,000	146,000	150,600	149,900	147,700	128,800	128,400	111,400	103,400	104,400	98,400	92,000	69,800	65,600	60,000	56,800	57,000	57,200	54,242	50,861	52,944	59,153	48,256	47,969	45,143	41,428	40,002	37,458	36,048	32,421
Equity in (gains) losses of affiliated companies
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-556	-	-	-	-741	-1,266	133	-156	771
Share-based employee benefit plan expense
0	0	0	0	13,000	11,000	9,000	-1,000	13,000	12,000	10,000	11,000	9,000	11,000	9,000	10,900	7,000	9,400	7,700	11,400	11,700	10,200	7,400	7,400	11,200	6,400	7,600	4,200	7,200	4,100	3,800	6,133	6,496	3,658	4,413	3,331	4,168	2,560	4,344	2,539	2,958	4,245	1,773
Derivative, Gain (Loss) on Derivative, Net
0	-23,000	-8,000	-14,000	19,000	-30,000	22,000	-58,000	46,000	-53,000	-7,000	24,000	-207,000	35,000	-21,000	-8,800	29,800	-3,000	7,000	58,900	100	-3,000	-1,900	13,800	-11,100	-1,200	7,200	142,000	-24,400	-18,900	-19,100	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized change in value of derivative instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,300	20,900	-4,400	-	-31,800	-12,800	33,800	-23,800	-47,000	8,300	-9,200	-	-	-	-2,435	-45,592	5,580	-11,069	-6,571	-18,338	2,133	41,428	-15,485
Realized losses (gains) on marketable securities available for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-500	-100	400	2,184	3,071	-109	-1,346	-1,045	6,558	1,056	4,962	3,962	9,880	22,138	-4,967
Other, net
36,000	40,000	-2,000	1,000	4,000	12,000	-2,000	6,000	-28,000	46,000	0	1,000	11,000	-3,000	1,000	-3,400	-26,400	4,400	-600	5,800	1,100	1,300	1,100	3,400	-7,500	-1,100	-5,800	-10,500	-8,400	2,600	4,500	-16,894	2,315	-2,036	715	-614	-335	-3,774	954	-11,599	835	613	1,436
Change in current assets and liabilities, excluding the effect of acquisitions and disposals:
Accounts receivable
-54,000	114,000	271,000	-47,000	68,000	110,000	47,000	97,000	64,000	92,000	-17,000	78,000	63,000	104,000	-23,000	159,200	4,900	81,400	59,500	120,300	-15,800	52,000	9,800	-37,300	63,900	-12,200	87,000	-4,500	72,000	-116,700	79,300	74,597	62,316	50,048	76,139	75,553	85,879	18,645	54,375	34,144	51,935	67,467	-30,931
Inventory
-12,000	21,000	-16,000	-51,000	-45,000	20,000	-6,000	5,000	5,000	22,000	10,000	-7,000	17,000	19,000	26,000	23,900	7,900	26,500	-7,300	22,900	14,500	12,100	7,000	27,100	17,400	19,400	25,800	23,400	12,300	8,500	25,500	2,776	-8,348	-24,666	-40,762	-25,095	7,299	-1,160	233	16,070	-788	-14,258	-2,564
Other operating assets
171,000	-21,000	-50,000	-319,000	51,000	152,000	171,000	-212,000	101,000	213,000	-29,000	43,000	-37,000	-61,000	-39,000	308,400	-29,200	20,400	26,400	3,100	-19,000	-6,800	-29,900	41,200	-4,000	89,400	-35,700	91,100	11,300	-93,100	-101,000	115,013	-35,161	13,176	-26,128	55,086	27,966	-22,662	-14,716	30,785	-5,498	31,684	-3,124
Assets held for sale, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,100	100	-	-1,357	-9,110	7,820	-	-	-	-	-	-	-	-
Accounts payable and other operating liabilities
13,000	99,000	-28,000	356,000	78,000	75,000	-219,000	245,000	-191,000	584,000	-365,000	455,000	109,000	185,000	-130,000	276,800	173,400	17,600	59,200	160,200	94,400	-131,600	111,500	136,500	53,200	179,800	-82,300	-31,000	150,000	-10,100	-40,700	100,856	125,895	61,843	-97,394	-38,003	74,021	45,447	-29,908	19,642	17,828	-18,268	-18,550
Income tax payable
-4,000	234,000	35,000	-371,000	156,000	-168,000	-10,000	2,064,000	132,000	29,000	4,000	143,000	62,000	74,000	22,000	318,100	11,100	17,000	15,800	11,400	2,900	13,500	11,300	35,400	11,300	3,000	7,700	13,600	-89,300	-410,300	30,500	15,181	36,593	19,438	24,088	53,108	25,260	-10,955	10,697	18,935	28,548	20,064	-27,724
Payment of contingent consideration
0	16,000	13,000	0	0	0	22,000	0	0	0	0	-	-	-	-	-	-	-	-	9,300	0	0	5,000	75,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-14,000	-35,000	-2,000	-6,000	27,000	28,000	-8,000	-3,000	22,000	0	1,000	-4,000	14,000	-5,000	2,000	-12,300	18,200	29,200	1,900	-3,400	3,100	4,100	4,200	-15,000	19,200	11,100	1,400	5,800	-2,600	-2,000	4,300	856	2,381	1,816	-6,953	13,403	3,333	2,324	1,824	1,165	1,350	786	490
Net cash provided by operating activities
2,172,000	2,167,000	1,476,000	2,343,000	1,924,000	1,229,000	-325,000	1,689,000	1,088,000	1,616,000	853,000	1,402,000	770,000	993,000	1,000,000	1,359,200	284,900	284,400	856,500	832,600	900,900	515,700	557,100	550,700	571,100	736,800	367,300	479,600	571,400	623,200	344,400	437,627	602,074	461,129	275,270	204,845	381,660	310,401	284,650	320,561	277,254	184,923	127,117
Cash flows from investing activities:
Proceeds from sales of debt securities available-for-sale
602,000	113,000	261,000	5,000	143,000	37,000	3,203,000	2,582,000	1,233,000	1,791,000	266,000	91,000	114,000	114,000	314,000	138,300	2,081,900	500,000	1,079,800	513,700	518,200	555,700	588,300	1,706,100	607,100	433,100	896,000	555,000	338,300	364,900	485,500	360,226	719,477	296,151	799,346	-	-	-	-	-	-	-	-
Purchases of debt securities available-for-sale
3,000	62,000	428,000	435,000	130,000	48,000	62,000	1,447,000	3,305,000	1,620,000	1,791,000	546,000	128,000	147,000	285,000	189,600	572,300	448,300	678,800	524,400	580,700	789,600	766,700	746,300	1,463,900	657,900	1,115,500	1,251,300	756,500	655,200	105,800	366,156	363,951	464,573	498,720	-	-	-	-	-	-	-	-
Capital expenditures
68,000	60,000	69,000	98,000	64,000	80,000	88,000	103,000	44,000	70,000	62,000	66,000	67,000	43,000	60,000	140,500	50,500	52,700	42,300	49,400	39,500	36,700	24,700	26,600	31,800	35,900	25,400	29,600	22,600	31,200	28,100	41,541	37,511	29,887	23,161	39,494	18,900	21,332	18,906	33,315	21,367	17,728	20,974
Proceeds from sales of equity investment securities
17,000	1,000	2,000	0	41,000	0	55,000	84,000	5,000	27,000	0	-	-	-	-	6,500	300	78,400	6,800	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in affiliated companies
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,310	-	293	916	550	0	1,903	636	1,064
Purchases of equity investment securities
11,000	35,000	61,000	73,000	21,000	37,000	118,000	18,000	236,000	79,000	77,000	185,000	32,000	11,000	79,000	56,700	16,100	172,700	27,500	9,000	35,900	5,000	17,500	19,200	17,500	4,900	5,500	0	800	24,200	5,000	65,897	-7,130	0	533	-	-	-	-	-	-	-	-
Proceeds from sales of marketable securities available for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	840,449	1,196,864	-	702,447	437,668	412,606
Purchases of marketable securities available for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,219,994	1,200,626	-	677,294	630,062	704,613
Payments for acquisition of business, net of cash acquired
0	0	0	0	0	0	8,648,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	352,200	-	-	-	-	2,314,769	0	0	337,608	-	-	-	0
Payment for acquisition of intangible asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,000	8,700	700	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-4,000	-	-	-	0	-	-	-	-	3,800	21,300	200	-500	18,600	400	1,100	400	-15,100	500	-300	800	-	-	-	-	-	-	-	-	0	0	0	-3,333
Purchases of investment securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,837	2,725	-	134	10,097	750
Net cash (used in) investing activities
137,000	-43,000	-295,000	-601,000	-31,000	-128,000	-5,658,000	1,098,000	-2,374,000	45,000	-1,660,000	-704,000	-112,000	-76,000	-110,000	-361,200	-6,137,500	-98,300	338,000	-72,900	-159,200	-985,800	-220,100	914,800	-916,500	-275,400	-251,500	-775,500	-428,100	-343,600	-6,400	65,696	142,525	-106,143	275,622	-2,904,472	1,573,348	-412,630	-363,551	-325,510	1,749	-220,855	-311,462
Cash flows from financing activities:
Payment for treasury shares
0	0	0	0	0	3,396,000	2,700,000	2,908,000	114,000	518,000	293,000	134,000	320,000	296,000	1,410,000	682,900	576,800	984,700	1,012,600	541,300	251,600	613,700	1,568,500	696,600	190,100	834,200	1,043,700	562,400	734,500	544,000	202,700	614,185	885,289	239,112	450,014	-	-	-	-	-	-	-	-
Proceeds from short-term borrowing
0	0	0	0	780,000	3,114,000	1,815,000	0	0	0	0	-	-	-	-	3,880,100	1,260,000	880,900	90,000	130,000	201,500	775,400	1,460,000	701,000	550,000	1,788,100	1,422,900	620,400	1,250,100	1,578,400	1,045,900	-	-	-	-	-	-	-	-	-	-	-	-
Principal repayments on short-term borrowing
0	0	0	-1,000	1,776,000	2,119,000	1,815,000	0	0	0	0	-	-	-	-	4,582,200	1,421,100	20,100	189,600	130,300	293,900	1,453,000	1,135,000	562,000	1,032,100	1,264,200	1,369,600	636,800	1,315,700	1,338,400	1,421,300	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of long-term debt
0	0	0	0	0	0	4,452,000	2,972,000	496,000	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of contingent consideration
0	-24,000	-58,000	40,000	0	0	-40,000	0	0	0	0	0	2,000	3,000	3,000	-19,200	3,800	1,200	5,200	4,500	600	4,000	1,200	1,200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,700	0	0	15,000	225,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from share-based compensation arrangements
102,000	177,000	84,000	15,000	83,000	2,000	44,000	48,000	250,000	203,000	184,000	168,000	115,000	14,000	62,000	47,800	100,000	-10,200	114,400	92,100	111,100	34,800	59,200	93,600	137,500	54,100	266,400	155,200	80,100	25,400	215,500	74,242	37,901	36,052	18,305	30,856	11,037	13,327	31,669	15,367	17,815	4,709	11,860
Excess tax benefit from share-based compensation arrangements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	69,500	89,700	84,500	104,200	56,400	60,400	29,600	30,400	57,800	44,600	36,600	29,400	-8,700	10,000	18,600	15,366	5,272	5,681	4,781	27,043	-6,857	3,710	12,228	-2,112	30,237	24,962	44,751
Net cash (used in) financing activities
102,000	-347,000	26,000	16,000	-913,000	-2,399,000	1,756,000	-1,292,000	132,000	-315,000	-109,000	-7,000	-203,000	-279,000	-1,345,000	-2,114,400	7,348,700	-43,200	-908,100	-351,500	-175,900	1,278,500	-1,168,500	-657,400	1,002,700	-211,600	-687,400	-394,200	758,000	-268,600	-344,000	-424,670	-573,023	-197,379	-426,928	1,217,489	4,180	-88,399	43,897	-46,844	-1,310	-70,329	56,611
Effect of currency rate changes on cash and cash equivalents
-21,000	4,000	-8,000	-4,000	-3,000	-18,000	33,000	7,000	5,000	41,000	19,000	-44,000	5,000	-20,000	20,000	-20,500	-10,400	20,200	-40,300	-29,100	-42,800	14,500	-6,300	3,300	23,400	-3,100	-23,200	65,000	-48,300	-9,600	7,600	-14,052	-24,693	3,445	11,900	1,281	17,189	-9,310	-11,622	2,910	6,519	19,399	-10,947
Net increase (decrease) in cash and cash equivalents
2,390,000	1,781,000	1,199,000	1,754,000	977,000	-1,316,000	-4,194,000	1,502,000	-1,149,000	1,387,000	-897,000	647,000	460,000	618,000	-435,000	-1,136,900	1,485,700	163,100	246,100	379,100	523,000	822,900	-837,800	811,400	680,700	246,700	-594,800	-625,100	853,000	1,400	1,600	64,601	146,883	161,052	135,864	-1,480,857	1,976,377	-199,938	-46,626	-48,883	284,212	-86,862	-138,681
Supplemental schedule of non-cash investing and financing activity:
Change in net unrealized (gain) loss on debt securities available-for-sale
0	-1,000	0	-18,000	0	0	9,000	1,284,000	-444,000	-2,000	-227,000	-202,000	-8,000	29,000	-382,000	119,600	-426,300	68,800	-77,100	297,100	64,600	48,000	84,300	-11,100	163,300	50,900	2,000	4,500	-1,700	900	-2,400	1,228	-124	-1,121	-3,683	3,672	-2,308	-9,569	-5,603	6,333	-9,069	-574	-16
Matured shares tendered in connection with stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-200	-	-	-	-	-9	-8,399	326	-163	-1,017	-400	-597	0
Supplemental disclosure of cash flow information:
Interest paid
281,000	109,000	281,000	108,000	281,000	110,000	190,000	78,000	199,000	64,000	198,000	64,000	198,000	64,000	201,000	71,900	50,900	70,000	50,200	70,000	50,300	23,700	52,200	23,400	21,600	23,500	22,300	23,400	500	23,500	1,000	-	-	-	-	114	0	1,638	0	-	-	-	-
Income taxes paid
172,000	56,000	275,000	191,000	188,000	399,000	387,000	25,000	117,000	205,000	128,000	28,000	118,000	125,000	102,000	15,400	98,400	140,500	106,700	19,600	81,600	96,800	96,600	65,700	71,400	78,200	76,600	100,000	197,200	87,000	85,400	13,841	12,470	33,736	32,953	6,685	31,949	42,817	40,525	9,547	8,231	10,270	42,491
Human Longevity
Investment in Human Longevity, Inc. common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	0	40,000	-	0	0	0	0	0	0	90,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-